Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
Syndax Pharmaceuticals (Nasdaq: SNDX) will host an in-person investor event with a live webcast on Monday, December 8, 2025 at 7:00 a.m. ET during the 67th American Society of Hematology (ASH) Annual Meeting.
Company management and multiple key opinion leaders will discuss data updates from the Revuforj (revumenib) and Niktimvo (axatilimab-csfr) programs. A live webcast and a replay will be available on the Investor section of the company website at www.syndax.com for a limited time.
Syndax Pharmaceuticals (Nasdaq: SNDX) organizzerà un evento per investitori in persona con trasmissione in diretta il lunedì 8 dicembre 2025 alle 7:00 ET durante la 67a riunione annuale della American Society of Hematology (ASH).
La direzione aziendale e molteplici opinion leaders discuteranno gli aggiornamenti sui dati dei programmi Revuforj (revumenib) e Niktimvo (axatilimab-csfr). Una trasmissione in diretta e una replica saranno disponibili nella sezione Investor del sito web della società all'indirizzo www.syndax.com per un periodo limitato.
Syndax Pharmaceuticals (Nasdaq: SNDX) organizará un evento para inversores en persona con transmisión en vivo el lunes, 8 de diciembre de 2025 a las 7:00 a. m. hora del Este durante la 67.ª Reunión Anual de la American Society of Hematology (ASH).
La dirección de la empresa y varios líderes de opinión discutirá actualizaciones de datos de los programas Revuforj (revumenib) y Niktimvo (axatilimab-csfr). Una transmisión en vivo y una reproducción estarán disponibles en la sección de Inversores del sitio web de la empresa en www.syndax.com por un tiempo limitado.
Syndax Pharmaceuticals (Nasdaq: SNDX)는 제67회 미국혈액학회(ASH) 연례 회의 기간 동안 2025년 12월 8일 월요일 오전 7:00 ET에 라이브 웹캐스트가 있는 대면 투자자 행사를 주최합니다.
회사 경영진과 다수의 주요 의견 리더들이 Revuforj (revumenib) 및 Niktimvo (axatilimab-csfr) 프로그램의 데이터 업데이트를 논의할 예정입니다. 라이브 웹캐스트와 재생은 회사 웹사이트의 투자자 섹션 www.syndax.com에서 일정 기간 동안 이용 가능합니다.
Syndax Pharmaceuticals (Nasdaq : SNDX) organisera un événement pour investisseurs en personne avec une diffusion en direct le lundi 8 décembre 2025 à 7 h 00 HE lors de la 67e réunion annuelle de l'American Society of Hematology (ASH).
La direction de l'entreprise et plusieurs leaders d'opinion clés discuteront des mises à jour des données des programmes Revuforj (revumenib) et Niktimvo (axatilimab-csfr). Une diffusion en direct et une rediffusion seront disponibles dans la section Investisseurs du site web de l'entreprise à l'adresse www.syndax.com pour une durée limitée.
Syndax Pharmaceuticals (Nasdaq: SNDX) wird während der 67. Jahrestagung der American Society of Hematology (ASH) eine persönliche Investorenveranstaltung mit Live-Übertragung veranstalten am Montag, dem 8. Dezember 2025 um 7:00 Uhr ET.
Das Management des Unternehmens und mehrere wichtige Meinungsführer werden Datenaktualisierungen der Programme Revuforj (revumenib) und Niktimvo (axatilimab-csfr) diskutieren. Eine Live-Übertragung und eine Wiederholung werden im Investorenbereich der Unternehmenswebsite unter www.syndax.com für eine begrenzte Zeit verfügbar sein.
Syndax Pharmaceuticals (Nasdaq: SNDX) سيُعقد حدث للمستثمرين حضورياً مع بث مباشر من شركة سيذنككس للأدوية خلال اجتماع الجمعية الأمريكية للدموية الـ67 (ASH) يوم الإثنين 8 ديسمبر 2025 في الساعة 7:00 صباحاً بتوقيت شرق الولايات المتحدة.
إدارة الشركة وكبار القادة في الرأي سيناقشون تحديثات البيانات لبرامجي Revuforj (revumenib) و Niktimvo (axatilimab-csfr). سيكون هناك بث مباشر وإعادة عرض متوفّران في قسم المستثمرين على موقع الشركة www.syndax.com لفترة محدودة.
- None.
- None.
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 8, 2025, at 7:00 a.m. ET during the 67th American Society of Hematology (ASH) Annual Meeting. Members of the Syndax management team will be joined by multiple key opinion leaders to discuss data updates from the Company’s Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) programs.
A live webcast of the event will be available on the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
When is the Syndax (SNDX) investor event at ASH 2025?
How can I watch the Syndax (SNDX) ASH investor presentation if I cannot attend in person?
What programs will Syndax (SNDX) discuss at the December 8, 2025 event?
Where is the Syndax (SNDX) investor event being held during ASH 2025?
Will the Syndax (SNDX) webcast be available after the live event?
